Loading data for ASND — first visit, this takes a few seconds.

Alert

Ascendis Pharma A/S (ASND)

NasdaqGS: ASND · Real-Time Price · USD

253.29

-1.52 (-0.60%)

At close: Aug 24, 2026, 6:14 PM

The price, the headline numbers and the latest news, in one place.

-0.60% (1D)

No data available

Bid	253.51
Market Cap	16.47B
Revenue (ttm)	1.05B
Net Income (ttm)	741.76M
	n/a
	13.07
	19.21
	26.34
P/B (ttm)	9.82
P/S (ttm)	15.73
Earnings Date	Apr 30, 2026

Ask	274.3
Volume	363,774
Avg. Volume (20D)	678,458
Open	253.62
Previous Close	254.81
Day's Range	252.87 - 257.88
52-Week Range	186.05 - 282.15
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ASND

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endo...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 28, 2015

Employees 1,189

Stock Exchange NasdaqGS

Ticker Symbol ASND

Website https://ascendispharma.com

Full Company Profile

Financial Performance

In 2025, Ascendis Pharma A/S's revenue was 720.13M, an increase of 98.03% compared to the previous year's 363.64M. Earnings were -228.03M, a decrease of -39.69%.

Financial Statements

Earnings Surprise

Ascendis Pharma A/S has released their quarterly earnings on Aug 13, 2026:

Revenue of $246.6M misses estimates by $0, with 144.27% YoY growth.
EPS of 0.9 exceeds estimates by 0.13, with 240.63% YoY growth.

Next Earnings Release

Ascendis Pharma A/S is scheduled to release its earnings on Apr 30, 2026, after market closes.
Analysts project revenue of ... Upgrade

News

3 days ago · Insider Monkey

Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine

On August 13, Ascendis Pharma (NASDAQ:ASND) reported second-quarter results that showed how far its rare disease portfolio has come. Total product revenue roughly doubled from a year earlier to €315 m...

4 days ago · Motley Fool

Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript

Revenue surged 105% year-over-year as three approved products scale globally.

4 days ago · Simply Wall St.

Is Ascendis Pharma (ASND) Priced Too Richly After Recent Progress?

Ascendis Pharma stock has delivered a 5.8% gain year to date, yet current valuation checks and market pricing point to a company that is not clearly cheap at today’s levels. With recent positive clini...

4 days ago · Simply Wall St.

Ascendis Pharma (ASND) Reports Earnings And Trial Updates, Is It Fully Priced?

Ascendis Pharma earnings and trial updates set the stage Ascendis Pharma (NasdaqGS:ASND) caught investor attention after reporting second quarter 2026 results on August 13, alongside fresh clinical up...

1 week ago · MT Newswires

Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says

Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of

Page 1 of 2

Ascendis Pharma A/S (ASND)